Storia in 2 fonti

What's Going On With Celcuity Stock On Tuesday? - Celcuity (NASDAQ:CELC)

Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-mutated breast cancer.

Raccontata da

endpoints.news

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo3 h fa

What's Going On With Celcuity Stock On Tuesday? - Celcuity (NASDAQ:CELC)

Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-mutated breast cancer.

originale

endpoints.news9 h fa

Celcuity aims for broad FDA approval after positive breast cancer readout

Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a third-quarter FDA submission.

Leggi questa versione → originale

Timeline cronologica

martedì 2 giugno 2026·endpoints.news
Celcuity aims for broad FDA approval after positive breast cancer readout
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a third-quarter FDA submission.
martedì 2 giugno 2026·benzinga.com
What's Going On With Celcuity Stock On Tuesday? - Celcuity (NASDAQ:CELC)
Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-mutated breast cancer.